.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
QuintilesIMS
Federal Trade Commission
Harvard Business School
Baxter
Moodys
Novartis
Accenture
McKesson
Chubb

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020779

« Back to Dashboard

NDA 020779 describes VIRACEPT, which is a drug marketed by Agouron Pharms and is included in three NDAs. It is available from four suppliers. Additional details are available on the VIRACEPT profile page.

The generic ingredient in VIRACEPT is nelfinavir mesylate. There are three drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nelfinavir mesylate profile page.

Summary for 020779

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Pharmacology for NDA: 020779

Medical Subject Heading (MeSH) Categories for 020779

Suppliers and Packaging for NDA: 020779

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIRACEPT nelfinavir mesylate TABLET;ORAL 020779 NDA H.J. Harkins Company, Inc. 52959-289 52959-289-06 6 TABLET, FILM COATED in 1 BOTTLE (52959-289-06)
VIRACEPT nelfinavir mesylate TABLET;ORAL 020779 NDA H.J. Harkins Company, Inc. 52959-289 52959-289-30 30 TABLET, FILM COATED in 1 BOTTLE (52959-289-30)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 250MG BASE
Approval Date:Mar 14, 1997TE:RLD:Yes

Expired Orange Book Patents for NDA: 020779

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Agouron PharmsVIRACEPTnelfinavir mesylateTABLET;ORAL020779-001Mar 14, 1997► Subscribe► Subscribe
Agouron PharmsVIRACEPTnelfinavir mesylateTABLET;ORAL020779-001Mar 14, 1997► Subscribe► Subscribe
Agouron PharmsVIRACEPTnelfinavir mesylateTABLET;ORAL020779-001Mar 14, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Federal Trade Commission
Mallinckrodt
Colorcon
Novartis
Chubb
McKesson
Boehringer Ingelheim
US Department of Justice
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot